Protection against enterovirus 71 with neutralizing epitope incorporation within adenovirus type 3 hexon

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Tian, Xingui ^a   Su, Xiaobo ^a   Li, Xiao ^a   Li, Haitao ^a,b   Li, Ting ^a   Zhou, Zhichao ^a   Zhong, Tianhua ^a   Zhou, Rong ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b University of Macau   (Macao)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ENHANCED GREEN FLUORESCENT PROTEIN; ENTEROVIRUS 71 VACCINE; EPITOPE; EPITOPE SP70; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; PROTEIN VP1; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADENOVIRUS; ADENOVIRUS 3; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG SYNTHESIS; ENTEROVIRUS 71; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNIZATION; IN VIVO STUDY; MOUSE; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PASSIVE IMMUNIZATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; THERMOSTABILITY; VIRION; VIROGENESIS; VIRUS NEUTRALIZATION;

ADENOVIRIDAE; HUMAN ADENOVIRUS TYPE 3; HUMAN ENTEROVIRUS 71; MIRIDAE; MUS;

EID: 84864397228     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041381     Document Type: Article

References (54)

1. Wong KT, Lum LC, Lam SK,(2000) Enterovirus 71 infection and neurologic complications. N Engl J Med 342: 356-358.
2. McMinn P, Stratov I, Nagarajan L, Davis S,(2001) Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin Infect Dis 32: 236-242.
3. Chen KT, Chang HL, Wang ST, Cheng YT, Yang JY,(2007) Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998-2005. Pediatrics 120: e244-252.
4. Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, et al.(1999) An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 341: 929-935.
5. Yang F, Ren L, Xiong Z, Li J, Xiao Y, et al.(2009) Enterovirus 71 outbreak in the People's Republic of China in 2008. J Clin Microbiol 47: 2351-2352.
6. Fujimoto T, Chikahira M, Yoshida S, Ebira H, Hasegawa A, et al.(2002) Outbreak of central nervous system disease associated with hand, foot, and mouth disease in Japan during the summer of 2000: detection and molecular epidemiology of enterovirus 71. Microbiol Immunol 46: 621-627.
7. Gilbert GL, Dickson KE, Waters MJ, Kennett ML, Land SA, et al.(1988) Outbreak of enterovirus 71 infection in Victoria, Australia, with a high incidence of neurologic involvement. Pediatr Infect Dis J 7: 484-488.
8. Zhang D, Lu J,(2010) Enterovirus 71 vaccine: close but still far. Int J Infect Dis 14: e739-743.
9. Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, et al.(2007) Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res 125: 61-68.
10. Foo DG, Alonso S, Chow VT, Poh CL,(2007) Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 9: 1299-1306.
11. Li X, Mao C, Ma S, Wang X, Sun Z, et al.(2009) Generation of neutralizing monoclonal antibodies against Enterovirus 71 using synthetic peptides. Biochem Biophys Res Commun 390: 1126-1128.
12. Sette A, Fikes J,(2003) Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr Opin Immunol 15: 461-470.
13. Dudek NL, Perlmutter P, Aguilar MI, Croft NP, Purcell AW,(2010) Epitope discovery and their use in peptide based vaccines. Curr Pharm Des 16: 3149-3157.
14. Purcell AW, McCluskey J, Rossjohn J,(2007) More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 6: 404-414.
15. Barouch DH,(2010) Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS 5: 386-390.
16. Zhu Y, Farina JB, Meshack S, Santovena A, Patel S, et al.(2010) Anti-tumor effects of adenovirus containing human growth hormone sequences in a mouse model of human ovarian cancer. Endocrine 37: 430-439.
17. Jones FR, Gabitzsch ES, Xu Y, Balint JP, Borisevich V, et al.(2011) Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine. Vaccine 29: 7020-7026.
18. Matthews QL,(2011) Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach. Mol Pharm 8: 3-11.
19. Crompton J, Toogood CI, Wallis N, Hay RT,(1994) Expression of a foreign epitope on the surface of the adenovirus hexon. J Gen Virol 75 (Pt 1): 133-139.
20. Matsui H, Sakurai F, Kurachi S, Tashiro K, Sugio K, et al.(2009) Development of fiber-substituted adenovirus vectors containing foreign peptides in the adenovirus serotype 35 fiber knob. Gene Ther 16: 1050-1057.
21. Krause A, Joh JH, Hackett NR, Roelvink PW, Bruder JT, et al.(2006) Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity. J Virol 80: 5523-5530.
22. Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, et al.(2006) Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441: 239-243.
23. McConnell MJ, Danthinne X, Imperiale MJ,(2006) Characterization of a permissive epitope insertion site in adenovirus hexon. J Virol 80: 5361-5370.
24. Wu H, Han T, Belousova N, Krasnykh V, Kashentseva E, et al.(2005) Identification of sites in adenovirus hexon for foreign peptide incorporation. J Virol 79: 3382-3390.
25. Matthews QL, Fatima A, Tang Y, Perry BA, Tsuruta Y, et al.(2010) HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach. PLoS One 5: e11815.
26. Youil R, Toner TJ, Su Q, Chen M, Tang A, et al.(2002) Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum Gene Ther 13: 311-320.
27. Wu H, Dmitriev I, Kashentseva E, Seki T, Wang M, et al.(2002) Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J Virol 76: 12775-12782.
28. Shiratsuchi T, Rai U, Krause A, Worgall S, Tsuji M,(2010) Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice. J Clin Invest 120: 3688-3701.
29. Zhang Q, Su X, Seto D, Zheng BJ, Tian X, et al.(2009) Construction and characterization of a replication-competent human adenovirus type 3-based vector as a live-vaccine candidate and a viral delivery vector. Vaccine 27: 1145-1153.
30. Stone D, Liu Y, Li ZY, Tuve S, Strauss R, et al.(2007) Comparison of adenoviruses from species B, C, E, and F after intravenous delivery. Mol Ther 15: 2146-2153.
31. Short JJ, Vasu C, Holterman MJ, Curiel DT, Pereboev A,(2006) Members of adenovirus species B utilize CD80 and CD86 as cellular attachment receptors. Virus Res 122: 144-153.
32. Sirena D, Lilienfeld B, Eisenhut M, Kalin S, Boucke K, et al.(2004) The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol 78: 4454-4462.
33. Crawford-Miksza L, Schnurr DP,(1996) Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. J Virol 70: 1836-1844.
34. Rux JJ, Kuser PR, Burnett RM,(2003) Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution x-ray crystallographic, molecular modeling, and sequence-based methods. J Virol 77: 9553-9566.
35. Pichla-Gollon SL, Drinker M, Zhou X, Xue F, Rux JJ, et al.(2007) Structure-based identification of a major neutralizing site in an adenovirus hexon. J Virol 81: 1680-1689.
36. Yuan X, Qu Z, Wu X, Wang Y, Liu L, et al.(2009) Molecular modeling and epitopes mapping of human adenovirus type 3 hexon protein. Vaccine 27: 5103-5110.
37. Matthews QL, Yang P, Wu Q, Belousova N, Rivera AA, et al.(2008) Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach. Virol J 5: 98.
38. Worgall S, Krause A, Rivara M, Hee KK, Vintayen EV, et al.(2005) Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. J Clin Invest 115: 1281-1289.
39. Lanzi A, Ben Youssef G, Perricaudet M, Benihoud K,(2011) Anti-adenovirus humoral responses influence on the efficacy of vaccines based on epitope display on adenovirus capsid. Vaccine 29: 1463-1471.
40. Foo DG, Macary PA, Alonso S, Poh CL,(2008) Identification of human CD4 T-cell epitopes on the VP1 capsid protein of enterovirus 71. Viral Immunol 21: 215-224.
41. Liu CC, Guo MS, Lin FH, Hsiao KN, Chang KH, et al.(2011) Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. PLoS One 6: e20005.
42. Liu JN, Wang W, Duo JY, Hao Y, Ma CM, et al.(2010) Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine 28: 7444-7451.
43. Ong KC, Devi S, Cardosa MJ, Wong KT,(2010) Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J Virol 84: 661-665.
44. Wu CN, Lin YC, Fann C, Liao NS, Shih SR, et al.(2001) Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20: 895-904.
45. Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, et al.(2008) Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 26: 1855-1862.
46. Tung WS, Bakar SA, Sekawi Z, Rosli R,(2007) DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther 5: 6.
47. Jia CS, Liu JN, Li WB, Ma CM, Lin SZ, et al.(2010) The cross-reactivity of the enterovirus 71 to human brain tissue and identification of the cross-reactivity related fragments. Virol J 7: 47.
48. Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, et al.(2011) Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine 29: 4362-4372.
49. Nagata N, Iwasaki T, Ami Y, Tano Y, Harashima A, et al.(2004) Differential localization of neurons susceptible to enterovirus 71 and poliovirus type 1 in the central nervous system of cynomolgus monkeys after intravenous inoculation. J Gen Virol 85: 2981-2989.
50. Arévalo MT, Xu Q, Paton JC, Hollingshead SK, Pichichero ME, et al.(2009) Mucosal vaccination with a multicomponent adenovirus-vectored vaccine protects against Streptococcus pneumoniae infection in the lung. FEMS Immunology & Medical Microbiology 55: 346-351.
51. Wang SM, Liu CC,(2009) Enterovirus 71: epidemiology, pathogenesis and management. Expert Rev Anti Infect Ther 7: 735-742.
52. Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, et al.(2010) Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 10: 778-790.
53. Yu CK, Chen CC, Chen CL, Wang JR, Liu CC, et al.(2000) Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J Biomed Sci 7: 523-528.
54. Tian X, Su X, Li H, Li X, Zhou Z, et al.(2011) Construction and characterization of human adenovirus serotype 3 packaged by serotype 7 hexon. Virus Res 160: 214-220.